You’ve tried the first antidepressant. Maybe the second. Maybe a combination your psychiatrist built carefully over months, adjusting doses and watching for side effects each time. You did the part that was asked of you, and the depression is still there. It is reasonable to wonder at this point whether anything will work, or whether this is simply how things are now.
This is treatment-resistant depression – a specific clinical designation, not a verdict on your case. In psychiatry, the term generally describes major depressive disorder that has not responded to at least two adequate trials of different antidepressant medications, each given at an appropriate dose for an appropriate length of time. Some clinicians now also use the term difficult-to-treat depression, a broader framework that looks past medication trials alone to the full picture of what a patient’s depression is and is not responding to. Dr. Gonzalo Laje, MD, MHCM, FAPA, founder of Washington Behavioral Medicine Associates (WBMA) and a psychiatrist with 25+ years of experience in psychopharmacology, sees this pattern often in practice. What follows is a look at why standard antidepressants stop working for some patients, the FDA-recognized paths that exist beyond them, and how a diagnostic-first, multidisciplinary practice approaches these cases.
In short – treatment-resistant depression (TRD) means major depressive disorder that has not improved after two or more adequate antidepressant trials. It is a diagnostic category, not a description of a patient’s effort or a permanent condition. Research supports several additional treatment paths once standard antidepressants have not worked.
What Is Treatment-Resistant Depression?
Not every difficult depression is treatment-resistant depression in the clinical sense. The threshold most psychiatrists work from, drawn from research on major depressive disorder, is two separate antidepressant trials, from two different medication classes, each taken at an adequate dose for an adequate length of time (usually six to eight weeks) without meaningful improvement. If that threshold is met, the diagnosis shifts from depression that needs an adjustment to depression that needs a different category of treatment.
Some researchers and clinicians now use a related term, difficult-to-treat depression, for cases where the goal shifts from remission at all costs toward the best achievable, sustainable level of symptom control given everything tried so far. Whichever term applies to a given patient, the practical question is the same. What treatment class, delivered which way, gives this patient’s biology the best chance of a response?
This distinction matters because the two framings sometimes lead to different care plans. A patient newly meeting TRD criteria after two medication trials may have several evidence-based options still ahead. A patient who has tried many combinations over years may benefit more from a full multidisciplinary care review than another single medication swap.
Research points to how common this pattern is. The NIMH-sponsored STAR*D study, the largest real-world clinical trial of depression treatment conducted to date, found that roughly one-third of participants did not achieve remission after two adequate antidepressant trials, meeting the clinical definition of treatment-resistant depression used throughout this article. That scale is part of why treatment-resistant depression is treated as an expected clinical category with its own evidence base, not a rare or unusual outcome.
The practical takeaway is that reaching this point in treatment is a signal to change strategy, not a signal to give up on treatment altogether. Standard antidepressants work through one biological pathway, primarily serotonin and norepinephrine signaling, and when that pathway has been tried twice without success, the evidence-based next step is typically a treatment that works through a different mechanism entirely rather than a third medication in the same class.
Signs and Symptoms Worth Bringing to a Psychiatrist
Treatment-resistant depression symptoms look like standard depression – low mood, loss of interest, sleep and appetite changes, difficulty concentrating, fatigue – but with one added pattern. They continue, largely unchanged, through more than one well-managed medication trial. These are the patterns patients often report.
- Little or no improvement after 6 to 8 weeks on an adequate antidepressant dose
- Partial response – some symptoms ease, but the depression does not lift
- Repeated relapse shortly after a medication seemed to be working
- Intolerable side effects that force a switch before a medication trial can run its full course
- Ongoing fatigue or cognitive fog that standard antidepressants have not touched
If two or more of these describe your experience, that is worth bringing directly to a psychiatric evaluation rather than a third round of the same type of medication.
Why Antidepressants Stop Working for Some Patients
Most first-line antidepressants, SSRIs and SNRIs, work by increasing the availability of serotonin or norepinephrine at the synapse. For a large share of patients, that mechanism is enough. For others, research points to different biological pathways driving the depression, which is one reason repeating the same mechanism at a higher dose often does not help.
Genetics can affect how a patient metabolizes a given medication, which is part of why genetic testing for psychiatric medications has become a useful tool for some patients. Emerging research also points to inflammation, metabolic factors, and changes in neuroplasticity as contributors to depression that does not respond to serotonin-focused treatment alone. This is part of why WBMA takes a diagnostic-first approach, working to understand what is driving a specific patient’s depression rather than defaulting to another trial-and-error medication switch.
The three interventional paths below work through mechanisms that are distinct from SSRIs and SNRIs, which is part of why they can be an effective option for some patients whose depression has not responded to first-line medication. Ketamine and esketamine act on the brain’s glutamate system, a different neurotransmitter pathway than the serotonin and norepinephrine systems targeted by standard antidepressants, and research suggests this may explain the more rapid response some patients experience. TMS works differently still, using magnetic pulses to stimulate a specific region of the prefrontal cortex associated with mood regulation, with research pointing to changes in neuroplasticity as part of the underlying mechanism.
Ruling Out Pseudo-Resistance Before Starting a New Treatment
Before moving to an interventional option, an evaluation should confirm that a patient’s depression is genuinely treatment-resistant rather than what clinicians sometimes call pseudo-resistance, meaning the medication trials themselves were not adequate for reasons that can be corrected. These are common factors worth reviewing first.
- Inadequate dose or duration – a medication trial ended before reaching a therapeutic dose or before the typical six to eight week window needed to see full effect
- Medication adherence – side effects or cost led to inconsistent use, which can look like non-response
- Misdiagnosis – depression that is part of bipolar disorder can appear treatment-resistant when treated with antidepressants alone, since bipolar depression often calls for a different medication approach
- Undiagnosed medical contributors – thyroid conditions, vitamin deficiencies, and other medical factors can drive depressive symptoms that will not resolve with antidepressants alone
- Co-occurring conditions – untreated anxiety, substance use, or sleep disorders can limit how much relief a depression treatment alone can provide
This is one reason psychological and neuropsychological testing plays a role for some patients working through treatment-resistant depression. A full diagnostic review can clarify whether a different medication trial, a combination approach, or one of the three paths below is the more appropriate next step.
Three FDA-Recognized Paths Beyond Standard Antidepressants
For patients who meet criteria for treatment-resistant depression, three interventional options have research and regulatory recognition behind them. Each has a different FDA status, delivery method, and timeline, summarized below.
| Treatment | FDA Status | Delivery Method | Typical Timeline |
|---|---|---|---|
| Esketamine (Spravato) | FDA-approved for treatment-resistant depression | Intranasal spray, administered in-office | Twice weekly initially, tapering over weeks |
| IV Ketamine | Off-label use | Intravenous infusion, administered in-office | Series of infusions over 2 to 3 weeks |
| TMS Therapy | FDA-cleared for major depressive disorder | Magnetic stimulation, non-invasive, in-office | Daily sessions over 4 to 6 weeks |
Esketamine (Spravato) is FDA-approved specifically for treatment-resistant depression in adults, used together with an oral antidepressant. Clinical research supports its use as a faster-acting option than standard antidepressants for some patients, though as with any treatment discussed here, individual results vary. Read more about Spravato and its benefits.
IV ketamine is used off-label for treatment-resistant depression, meaning it is not FDA-approved for this specific indication but is supported by a body of clinical research and prescribed based on physician judgment. Many patients experience symptom relief within days of an infusion series, though responses vary by individual. Learn more about our ketamine therapy program.
TMS therapy is FDA-cleared for major depressive disorder and works through a mechanism entirely separate from medication, using repeated magnetic pulses targeting a specific region of the brain involved in mood regulation. It is non-invasive and carries a different side effect profile than either ketamine option. Explore TMS therapy at WBMA or read about what to expect from TMS side effects.
Patients and families often ask which of these three is the strongest option. There is no single answer – the right path depends on medical history, prior medication response, and a patient’s own priorities around timeline and delivery method. For a side-by-side look at how the two most commonly compared paths differ in practice, see our detailed ketamine vs TMS therapy comparison.
Cost and insurance coverage are also part of this decision, and they vary by treatment. Because Spravato carries FDA approval for treatment-resistant depression, many insurance plans cover it under certain criteria, though prior authorization is often required. TMS is FDA-cleared for major depressive disorder and is covered by many major insurers, typically after documentation of prior medication trials. IV ketamine, since it is used off-label, is less consistently covered and is more often self-pay. A psychiatric evaluation is the most direct way to find out which of these paths your specific insurance plan supports.
How WBMA Approaches Treatment-Resistant Depression
Few DC-metro practices offer psychiatry, therapy, neuropsychiatric testing, and all three interventional paths above under one roof. That matters for treatment-resistant depression specifically, because the path forward is often not obvious from a first conversation. It can call for a full review of past medication management, a look at whether testing could clarify the diagnosis, and a conversation about which interventional option fits a patient’s life.
Dr. Gonzalo Laje founded WBMA in 2009 and has spent 25+ years in psychopharmacology, with double board certification in child, adolescent, and adult psychiatry and 57+ peer-reviewed publications. That depth of experience with medication-resistant cases is part of why WBMA’s approach starts with a diagnostic review rather than another medication swap. Learn more about Dr. Laje’s background and approach.
A typical evaluation for treatment-resistant depression at WBMA begins with a review of every medication trial to date, including dose, duration, and response, since that history often points directly toward what to try next. From there, the care team can bring in psychological testing to rule out an underlying or co-occurring condition, a psychiatric consultation to discuss the three interventional paths above, and ongoing therapy where it fits the patient’s broader treatment goals. Because psychiatry, testing, and neuromodulation all operate under one roof, patients do not need to coordinate referrals across separate practices to move through this process.
Treatment goals often include reducing symptom burden, restoring day-to-day function, and building a sustainable plan, not a promise of a specific outcome, since every patient’s biology and history are different. That is why every conversation at WBMA about treatment-resistant depression starts with a full clinical picture, not a single treatment recommendation.
Frequently Asked Questions
What qualifies as treatment-resistant depression?
Most psychiatrists use a threshold of two adequate antidepressant trials, from different medication classes, each given at an appropriate dose for an appropriate length of time, without meaningful improvement. This is a clinical diagnostic marker, not a judgment on the patient, and research suggests it applies to a meaningful share of people treated for major depressive disorder.
What is the difference between treatment-resistant depression and difficult-to-treat depression?
Treatment-resistant depression is generally defined by a specific number of failed medication trials. Difficult-to-treat depression is a broader framework some clinicians use for cases where the practical goal shifts toward the best sustainable symptom control, considering everything tried so far, including therapy and lifestyle factors, rather than a fixed trial count.
Why do antidepressants stop working for some people?
Research points to several possible factors, including how an individual’s genetics affect medication metabolism, and biological pathways such as inflammation or changes in neuroplasticity that a standard SSRI or SNRI does not address. Before assuming true resistance, it is also worth ruling out an inadequate dose, an undiagnosed medical contributor, or a misdiagnosis, since any of these can look like resistance without being true treatment-resistant depression.
Is IV ketamine or Spravato better for treatment-resistant depression?
Neither is universally the better choice. Spravato (esketamine) is FDA-approved specifically for treatment-resistant depression and delivered as an intranasal spray, while IV ketamine is used off-label and delivered by infusion. Coverage also differs, since Spravato is more consistently covered by insurance while IV ketamine is more often self-pay. The right choice depends on medical history, coverage, and a patient’s preferences, which is a conversation best had directly with a psychiatrist.
How long does it take for a treatment like TMS to start working?
TMS is typically delivered in daily sessions over 4 to 6 weeks. Many patients experience symptom improvement over the course of the full series rather than immediately, though individual timelines vary, and a psychiatrist can help set realistic expectations based on a patient’s specific history.
If standard antidepressants have not helped, you have not run out of options. A full evaluation can clarify which of these paths fits your specific case.
Individual results may vary. Treatment effectiveness depends on each patient’s unique circumstances. This information is for educational purposes and should not replace a professional consultation. For more on the research behind these treatments, see the National Institute of Mental Health’s depression research and the FDA’s approval announcement for esketamine.
